MIR105 (MicroRNA 105)

GHET1 emerges as a promising prognostic biomarker and tumor promoter in esophageal cancer, functioning through the modulation of miR-105-3p.

This review provides a comprehensive overview of the current and future applications of liquid biopsy in TNBC management, highlighting its potential to improve early disease detection, optimize therapeutic strategies, and refine patient classification. Integrating liquid biopsy into routine clinical practice could lead to better treatment outcomes and more personalized approaches to TNBC care.

Distinct miRNA expression profiles are associated with progressive stages of laryngeal mucosal lesions. Specific miRNAs may serve as valuable biomarkers for early detection, risk stratification, and prognosis in vocal fold carcinogenesis.

The study reports a simple, unique HCA-FRET biosensor which undergo dual target miR-155 and miR-105 biomarkers detection enabling early breast cancer diagnosis. Compared with the traditional single marker detection or two signal output analysis methods, this strategy allows more accurate diagnosis of breast cancer patients from normal people. More importantly, through testing the clinical serum samples, we found that this method is expected to be used to distinguish breast cancer patients from normal people. Therefore, the proposed method has great potential applications for nucleic acid based clinical diagnostics.

A detailed study reveals that RBMY1A1-dependent sorting of miR-105-5p into fibroblasts and subsequent internalization of miR-105-5p promote the transformation of NFs to CAFs by downregulating LATS2 expression and activating NF-κB signaling, which concurrently facilitates the EMT of breast cancer cells. Thus, our results indicate that exosomal miR-105-5p may be a potential target for novel therapeutic strategies to prevent the coevolution of breast cancer cells and CAFs.

Further bioinformatic analysis revealed that LINC00261 regulates key cellular processes, such as protein-DNA complex formation, ribonuclease complex activity, histone deacetylase complexes, and nuclear matrix interactions. Overall, we believe that LINC00261 holds significant promise as a future biomarker and, when combined with existing treatment strategies, may enhance cancer patient care and survival.

It also distinctly deactivated the NF-κB pathway. To sum up, these data indicated that miR-105-5p depletion might impede EMT, yet enhance the immune response in CC by elevating PTEN expressions via deactivation of the NF-κB pathway.

This research enhances our understanding of the pathogenesis of this malignancy. With the potential to detect cancer at its earliest stages, timely treatment could significantly improve patient survival rates.

[This retracts the article DOI: 10.18388/abp.2023_6398.].

Our results indicate that KIFC1 might be involved in DNA repair and cell cycle regulation in LIHC cells which subsequently impacts tumor cell proliferation; moreover, miR-105 influences hepatoma cell line proliferation via its interaction with KIFC1. Collectively, these results highlight the potential therapeutic significance of targeting KIFC1 for chemotherapy treatment in LIHC patients.

miR-105-5p promotes HDAC2 expression by reducing FOXG1, inhibits histone acetylation, and aggravates the malignant biological behavior of TNBC cells.

Lauren classification was an independent prognostic factor in GC. MiR-141-3p was an independent prognostic factor and a promising prognostic biomarker in Lauren classification GC.